Coya’s focus is on generating safe, tolerable, and efficacious therapeutics that minimally burden the patient and caregiver and exponentially improve outcomes over the current standard of care
A 5-minute infusion in an outpatient facility with patients leaving the office within 1 – 2 hours. Proprietary technology enables multiple infusions over the course of the year
A limiting feature of Tregs has been their instability and inability to cryopreserve for maintenance therapy. Coya has perfected this process allowing a patient to be treated long term with highly viable and neuroprotective cells
Coya’s Technology
Proprietary Platform Technology and Scalable Manufacturing Process Overcomes Supply Chain Management Barriers
TAI™ (Tregs Against Inflammation) platform offers potential therapeutic approaches to address the unmet and significant medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and other neurodegenerative and autoimmune diseases.
 |
||||
| 1. Collection Draw one-time sample from patient |
2. Convert & Expand Coya’s CTregTM platform (cryopreservation for Tregs) is the first in the industry to convert dysfunctional Tregs to functional Tregs and expand to the billions of cells No genetic manipulation required |
3. Cryopreserve Cryopreserve Tregs for one year of monthly maintenance infusions |
4. Ship, Thaw & Administer Ship cells to outpatient infusion center Thaw cells and provide monthly recurring infusions to patient allowing for an ‘off the shelf’ Treg cell therapy that has not been feasible to date |
|
Dr. Stanley Appel “Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great promise in unlocking a new treatment paradigm and will enable us to revolutionize care for patients with devastating neurodegenerative diseases.”
